Taylan F, Staffas A, Sjögren S, Lagerstedt-Robinson K, Kuchinskaya E, Poluha A, Ivarsson S, Hellberg M, Klar J, Abel F, Abrahamsson J, Pronk CJ, Belander Strålin K, Harila A, Vogt H, Norén-Nyström U, Grillner P, Palmqvist L, Arvidsson L, Pandzic T, Bondeson ML, Mu N, Ekholm K, Anderlid BM, Golovleva I, Maya-González C, Gideonsson P, Tham E, Barbany G, Lähteenmäki P, Sandgren J, Rosenquist R, Wirta V, Ljungman G, Gisselsson D, Palle J, Tesi B, Nordgren A
Nat Commun 17 (1) - [2026-09-28; online 2026-09-28]
The utility of whole-genome sequencing (WGS) for detecting childhood leukemia predisposition remains unclear. We perform a nationwide, prospective, population-based study of 181 children with acute leukemia to assess diagnostic yield and clinical utility of a uniformly applied three-pronged strategy, including systematic phenotyping, germline WGS-based 189-gene panel and tumor sequencing of positive cases. Trio-WGS is performed in 11 high-suspicion families. Nine patients have pathogenic germline alterations: six (3.3%) with leukemia predisposition syndromes (TP53, CEBPA, DNMT3A, trisomy 21) and three (1.6%) with solid tumor predisposition syndromes (MSH6, PALB2, SDHA). Trio-WGS identifies one likely-pathogenic de novo DNMT3A variant. Six of nine diagnoses are previously unrecognized. Findings lead to tailored surveillance in 8/9 patients and treatment modifications in 4/9. Here, we show that this strategy gives a modest diagnostic yield. Nevertheless, the actionability of the findings supports its feasibility and validity in practice. Whether to restrict analysis to leukemia-relevant genes or broaden the panel should reflect local resources and counseling capacity.
Clinical Genomics [Collaborative]
Clinical Genomics Uppsala [Collaborative]
PubMed 42806009
DOI 10.1038/s41467-026-78170-z
Crossref 10.1038/s41467-026-78170-z
pmc: PMC13619629
pii: 10.1038/s41467-026-78170-z